Connective Tissue Disease–Associated Interstitial Lung Disease (CTD-ILD)

What CTD-ILD means

Connective tissue disease-associated interstitial lung disease, or CTD-ILD, is interstitial lung disease that develops as a manifestation of an underlying autoimmune or rheumatologic condition. Rather than arising on its own with no identifiable cause, CTD-ILD occurs alongside a systemic autoimmune process also affecting other parts of the body. Because the two are linked biologically, they are generally evaluated and treated together.

This distinction matters because CTD-ILD is one specific, identifiable category within the broader ILD umbrella, distinct from idiopathic pulmonary fibrosis (IPF), which by definition has no identifiable underlying cause. The two can sometimes look similar on imaging, but their expected course, monitoring approach, and treatment strategy can differ meaningfully.

CTD-ILD is also distinct from exposure-related forms of ILD, such as hypersensitivity pneumonitis, where an inhaled trigger rather than an autoimmune process drives the lung inflammation. Distinguishing an autoimmune cause from an exposure-related one is part of a thorough ILD evaluation.

The main autoimmune diseases associated with ILD

CTD-ILD is not linked to one single autoimmune disease. Several distinct connective tissue diseases are recognized causes, summarized above, and it is worth understanding that the risk of developing ILD is not the same across all of them.

It is important not to treat every autoimmune disease as carrying the same lung risk. As the summary above reflects, the likelihood of developing ILD, its typical pattern, and expected course vary meaningfully from one connective tissue disease to another, which is why identifying the specific underlying condition is central to CTD-ILD evaluation rather than a secondary detail.

Lung findings can come before the diagnosis

One of the clinically important features of CTD-ILD is that it does not always follow the sequence patients might expect. In some people, findings such as an abnormal chest CT or unexplained exertional shortness of breath appear before the joint pain, skin changes, muscle weakness, dry eyes, or other systemic symptoms of the underlying autoimmune disease are recognized.

In these situations, the lung findings can be the first clue that leads to a closer look for an underlying connective tissue disease. This is one reason pulmonologists routinely consider autoimmune causes, and often involve rheumatology, when evaluating unexplained ILD, even in a patient who has not yet been diagnosed with a rheumatologic condition.

Common symptoms

The respiratory symptoms of CTD-ILD, summarized above, closely resemble other forms of interstitial lung disease: gradually worsening shortness of breath with exertion and a persistent dry cough that lingers without an obvious explanation are the most common presenting complaints.

Because CTD-ILD occurs alongside an underlying autoimmune disease, additional symptoms related to that condition, also summarized above, may be present depending on which specific connective tissue disease is involved. These systemic symptoms may appear before, alongside, or, as noted above, sometimes after the respiratory symptoms.

How CTD-ILD is diagnosed

Diagnosing CTD-ILD draws on several types of evaluation together, since no single test identifies both the lung disease and its autoimmune cause on its own. The steps below outline how that evaluation typically unfolds.

The Diagnostic Pathway

1. 01→High-Resolution CT (HRCT)Detailed, thin-slice imaging identifies the pattern and extent of inflammation or scarring present. Several HRCT patterns can occur in CTD-ILD, including a nonspecific interstitial pneumonia pattern, which is relatively common in this setting, and, in some cases, a usual interstitial pneumonia pattern similar to what is classically seen in IPF.↓
2. 02Pulmonary Function Testing and DLCOBreathing tests generally show a restrictive pattern, meaning measured lung volumes are reduced because the affected lung tissue cannot expand fully. DLCO, which estimates how efficiently oxygen crosses into the bloodstream, is frequently reduced and can decline before other measurements show a clear change; both establish a baseline used for later comparison.↓
3. 03→Serologic and Rheumatologic EvaluationBlood tests for autoantibodies associated with specific connective tissue diseases are standard, particularly when someone presents with ILD and no prior autoimmune diagnosis. Combined with a detailed history and physical exam for joint, skin, muscle, or other systemic findings, this helps identify or confirm which connective tissue disease is present; a rheumatology referral is a standard part of this evaluation.↓
4. 04Lung Biopsy, When NeededTissue sampling is not needed in every case and is generally reserved for situations where the diagnosis remains genuinely unclear after imaging, serologic testing, and clinical evaluation.

Why multidisciplinary co-management matters

CTD-ILD sits at the intersection of two organ systems and two medical specialties, reflected directly in how it is managed. Rheumatology brings expertise in diagnosing and managing the underlying autoimmune disease, including autoantibody patterns and disease activity outside the lungs. Pulmonology brings expertise in characterizing lung involvement and monitoring the respiratory disease over time.

Because treatment decisions often need to weigh the autoimmune disease and the lung disease together, ongoing co-management between pulmonology and rheumatology is the standard approach rather than an occasional referral. This helps ensure treatment aimed at each is working in concert rather than at cross purposes.

Treatment depends on the specific disease and pattern

There is no single, universal treatment plan for CTD-ILD, and this is worth stating clearly because it is easy to assume otherwise. Treatment depends heavily on which specific underlying connective tissue disease is present, the radiographic and pathologic pattern of lung involvement, and whether the disease behaves as predominantly inflammatory or as progressive fibrosis, summarized below.

Two people with CTD-ILD tied to different autoimmune conditions, or even the same underlying condition with different lung patterns, may be managed quite differently.

Immunomodulatory therapy, as a concept. Because CTD-ILD arises from an underlying autoimmune process, treatment aimed at calming an overactive immune response is central to managing many cases, particularly when inflammation is prominent. The specific approach is individualized and generally decided in coordination between pulmonology and rheumatology rather than by one specialty alone.

Antifibrotic therapy, as a concept. For some people who develop a progressive fibrotic pattern, meaning the lung scarring continues to worsen despite other measures, an antifibrotic approach may be considered, conceptually similar to how it is used for IPF. This is not relevant for everyone with CTD-ILD; whether it fits is a determination made individually by a pulmonologist.

Supportive care. Pulmonary rehabilitation, which combines supervised exercise training with breathing technique and energy conservation education, along with supplemental oxygen when exertional oxygen levels are affected, is relevant for many people with CTD-ILD regardless of the specific underlying disease, as a complement to disease-specific treatment rather than a replacement for it.

Because the right treatment approach depends so directly on getting the specific diagnosis right, an accurate characterization of both the underlying autoimmune disease and the pattern of lung involvement is the foundation that these treatment decisions are built on.

Ongoing monitoring

CTD-ILD generally requires ongoing follow-up rather than a single evaluation and treatment plan. Regularly repeated pulmonary function testing, including DLCO, helps track trends in lung volumes and gas exchange over successive visits, which is often more informative than any single measurement in isolation. Periodic imaging and symptom review are typically part of this same monitoring process.

A six-minute walk test or similar exercise-based assessment is also commonly used in CTD-ILD monitoring. Some people have normal oxygen saturation at rest but experience a meaningful drop during physical activity, and an exercise-based test can identify this exertional desaturation, which is useful both for understanding how the disease affects daily function and for determining whether supplemental oxygen during exertion is appropriate.

Because CTD-ILD can behave quite differently depending on the underlying autoimmune disease and the specific pattern of lung involvement, the frequency and combination of monitoring tools are tailored to each person’s individual situation, generally with input from both pulmonology and rheumatology.

Getting an accurate diagnosis

Because CTD-ILD spans several distinct underlying autoimmune diseases, each with its own typical risk level, pattern, and expected course, and because it can sometimes appear before an autoimmune diagnosis has been made, a thorough evaluation that includes both pulmonology and rheumatology gives the clearest picture of what is actually present and which treatment approach is most likely to help.

For patients in the North Dallas-Fort Worth area, the pulmonary team at VitalAir Sleep & Lung Center in Frisco offers pulmonary function testing and evaluation for unexplained shortness of breath or persistent cough, an appropriate starting point when CTD-ILD or another form of ILD is a consideration.